Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06384157 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder
A Phase 2 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT06384157 is a Phase 2 study that has completed, run by Indivior. The registered enrollment target is 300 participants.
The verdict
NCT06384157, a Phase 2 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to measure safety and efficacy and to determine dose-response relationship for INDV-2000 in participants with moderate to severe Opioid Use Disorder (OUD) who are new to treatment, have recently initiated or completed short-term medically supervised withdrawal with transmucosal (TM) buprenorphine, and are interested in transitioning to a non opioid treatment.
Interventions
- OTHER Placebo
- DRUG INDV-2000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-06-10 |
| Est. Completion | 2025-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06384157
The ClinicalTrials.gov registry entry for NCT06384157 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06384157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06384157 about?
NCT06384157 is a clinical study titled "Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder". The purpose of this study is to measure safety and efficacy and to determine dose-response relationship for INDV-2000 in participants with moderate to severe Opioid Use Disorder (OUD) who are new to treatment, have recently initiated or completed short-term medically supervised withdrawal with trans...
What is the current status of trial NCT06384157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2024-06-10. Estimated completion is 2025-11-03.
What interventions are being tested in trial NCT06384157?
The interventions under investigation include: Placebo (OTHER), INDV-2000 (DRUG).
Who is sponsoring clinical trial NCT06384157?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.